Notes from the Field: Rickettsia parkeri Rickettsiosis — Georgia, 2012–2014

Anne Straily, DVM1,2; Amanda Feldpausch, MPH3; Carl Ulbrich, DO4; Kiersten Schell4; Shannon Casillas, MPH3; Sherif R. Zaki, MD, PhD5; Amy M. Denison, PhD5; Marah Condit, MS2; Julie Gabel, DVM3; Christopher D. Paddock, MD2 (View author affiliations)

View suggested citation
Article Metrics
Altmetric:
Citations:
Views:

Views equals page views plus PDF downloads

Related Materials

During 2012–2014, five cases of Rickettsia parkeri rickettsiosis were identified by a single urgent care practice in Georgia, located approximately 40 miles southwest of Atlanta. Symptom onset occurred during June–October, and all patients had a known tick bite. Patients ranged in age from 27 to 72 years (median = 53 years), and all were male. The most commonly reported initial signs were erythema (n = 3) and swelling (n = 2) at the site of the bite. Two patients reported fever and a third patient reported a rash and lymphadenopathy without fever. Other symptoms included myalgia (n = 3), chills (n = 3), fatigue (n = 2), arthralgia (n = 2), and headache (n = 2). Eschar biopsy specimens were collected from each patient using a 4-mm or 5-mm punch and placed in 10% neutral buffered formalin or sterile saline. These specimens were tested by immunohistochemical (IHC) stains, quantitative polymerase chain reaction (qPCR) assays, or cell culture isolation to determine if there was evidence of infection with a Rickettsia species (1). IHC evidence of spotted fever group rickettsiae was found in the eschar biopsy specimens in all five cases. In four cases, the biopsy specimens were also positive for R. parkeri by qPCR. The fifth case (specimen positive only by IHC testing) was considered a probable R. parkeri case based on clinical signs and symptoms. R. parkeri was grown in cell culture from one specimen from which isolation was attempted. All patients were treated with oral doxycycline (100 mg twice daily) for a minimum of 10 days, and all recovered.

R. parkeri, recently recognized as a pathogen of humans, is transmitted by Amblyomma maculatum (Gulf Coast) ticks (Figure). The disease in humans is most commonly characterized by a necrotic, ulcerated, or scabbed lesion at the tick bite site, known as an inoculation eschar (Figure), which is generally followed by the patient experiencing some combination of fever, headache, malaise, and a sparse maculopapular or vesiculopustular rash (1). The first confirmed human infection with R. parkeri was described in 2004; through June 2016, a total of 39 cases, predominantly from the southeastern United States, have been documented in the scientific literature or confirmed by laboratory assays at CDC (2,3). The incidence of R. parkeri rickettsiosis in the United States is unknown. Serological assays currently used to diagnose spotted fever group rickettsial infections lack species-specificity, and there is considerable cross-reactivity among pathogens. It is likely that some, or possibly many, of the approximately 13,500 noncharacterized cases of spotted fever group rickettsioses reported in the United States during 2008–2012 were caused by R. parkeri (4).

The identification of five cases of R. parkeri rickettsiosis from one medical practice during a 3-year interval suggests that this disease is underrecognized in Georgia. During 2012–2014, a total of 335 cases of spotted fever group rickettsiosis were reported in Georgia, including 38 from the health district where the urgent care practice is located.* Four cases of R. parkeri rickettsiosis recently were diagnosed by one clinician in southern Mississippi (5), indicating that the disease might be more common throughout the range of A. maculatum than currently realized.

The recognized range of A. maculatum has increased considerably during the past 70 years and now includes most states in the southeastern United States (1). Clinicians should suspect R. parkeri rickettsiosis in patients who have febrile illnesses after being bitten by a tick, particularly in patients with an eschar at the bite site. Eschar biopsy samples are the most versatile diagnostic specimen and can be tested by IHC stains, qPCR assays, or cell culture isolation techniques; alternatively, a sterile swab of the eschar can be tested using qPCR and is less invasive than a biopsy (6). These tests are not widely available but can be performed at CDC and some academic hospitals (3). Because different spotted fever rickettsioses vary greatly in severity, species-specific diagnoses provide more accurate determinations of hospitalization and case-fatality rates associated with each disease. Doxycycline is the recommended treatment for all patients with a tickborne rickettsial infection, including R. parkeri rickettsiosis (3). Infection with R. parkeri rickettsiosis and other tickborne rickettsial diseases can be minimized by avoiding contact with ticks and by promptly removing attached or crawling ticks after exposures to tick-infested habitats. Persons should use Environmental Protection Agency–approved repellent products and check themselves, their children, and their pets after spending time in tick-infested habitats (3).

Corresponding author: Anne Straily, astraily@cdc.gov, 404-718-1422.


1Epidemic Intelligence Service, CDC; 2Rickettsial Zoonoses Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 3Georgia Department of Public Health; 4Summit Urgent Care Clinic, Newnan, Georgia; 5Infectious Diseases Pathology Branch, Division of Vector-Borne Diseases, CDC.

References

  1. Paddock CD, Finley RW, Wright CS, et al. Rickettsia parkeri rickettsiosis and its clinical distinction from Rocky Mountain spotted fever. Clin Infect Dis 2008;47:1188–96. CrossRef PubMed
  2. Paddock CD, Goddard J. The evolving medical and veterinary importance of the Gulf Coast tick (Acari: Ixodidae). J Med Entomol 2015;52:230–52. CrossRef PubMed
  3. Biggs HM, Behravesch CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis—United States. MMWR Recomm Rep 2016(No. RR-2).
  4. Drexler NA, Dahlgren FS, Heitman KN, Massung RF, Paddock CD, Behravesh CB. National surveillance of spotted fever group rickettsioses in the United States, 2008–2012. Am J Trop Med Hyg 2016;94:26–34. CrossRef PubMed
  5. Ekenna O, Paddock CD, Goddard J. Gulf coast tick rash illness in Mississippi caused by Rickettsia parkeri. J Miss State Med Assoc 2014;55:216–9. PubMed
  6. Myers T, Lalani T, Dent M, et al. Detecting Rickettsia parkeri infection from eschar swab specimens. Emerg Infect Dis 2013;19:778–80. CrossRef PubMed

* Data from the State Electronic Notifiable Disease Surveillance System, Georgia Department of Public Health Epidemiology Section (https://dph.georgia.gov/epidemiology).

Return to your place in the textFIGURE. Female (A) and male (C) Gulf Coast ticks (Amblyomma maculatum); (B) necrotic, ulcerated or scabbed lesion at the tick bite site, known as an inoculation eschar; and (D) immunohistochemical stain indicating the presence of a spotted fever group Rickettsia species in the tissue


Suggested citation for this article: Straily A, Feldpausch A, Ulbrich C, et al. Notes from the Field: Rickettsia parkeri Rickettsiosis — Georgia, 2012–2014. MMWR Morb Mortal Wkly Rep 2016;65:718–719. DOI: http://dx.doi.org/10.15585/mmwr.mm6528a3.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

View Page In: PDF [122K]